Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.
about
Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancerIntravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancerUpdate on the management of non-muscle invasive bladder cancer.Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial.Detection of microRNAs in archival cytology urine smears.Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.Prognostic value and efficacy valuation of postoperative intravesical instillation in primary urothelial carcinomas of upper urinary tract.Use of nomograms for predictions of outcome in patients with advanced bladder cancer.Pharmacokinetics of quercetin-loaded nanodroplets with ultrasound activation and their use for bioimagingUrine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies.Surveillance and treatment of non-muscle-invasive bladder cancer in the USA.GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.Pharmacogenetic association between XRCC1 polymorphisms and improved outcomes in bladder cancer patients following intravesical instillation of epirubicin.Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study.Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinomaThe association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytesDirect quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancerClinical Behavior of Bladder Urothelial Carcinoma in Young Patients: A Single Center Experience.Emerging intravesical therapies for management of nonmuscle invasive bladder cancerNew therapeutic targets in the management of urothelial carcinoma of the bladderStrategies to improve drug delivery in bladder cancer therapy.Outcomes of BCG Induction in High-Risk Non-Muscle-Invasive Bladder Cancer Patients (NMIBC): A Retrospective Cohort Study.Investigational therapies for non-muscle invasive bladder cancer.Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.Intravesical therapy for urothelial carcinoma of the bladder.Urothelial carcinoma of the bladder: definition, treatment and future efforts.Glycan-targeted drug delivery for intravesical therapy: in the footsteps of uropathogenic bacteria.Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation.Synthesis and functions of well-defined polymer-drug conjugates as efficient nanocarriers for intravesical chemotherapy of bladder cancer(a).Biomimetic delivery strategies at the urothelium: targeted cytoinvasion in bladder cancer cells via lectin bioconjugates.Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system.Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).Recommended oral sodium bicarbonate administration for urine alkalinization did not affect the concentration of mitomycin-C in non-muscle invasive bladder cancer patients.Landmarks in non-muscle-invasive bladder cancer.Lidocaine enhances the effects of chemotherapeutic drugs against bladder cancer.The use of water-soluble mucoadhesive gels for the intravesical delivery of epirubicin to the bladder for the treatment of non-muscle-invasive bladder cancer.
P2860
Q22001096-2FE1AD70-2AA6-4D70-84CE-DA489B929C10Q24234614-5FA9493D-954A-4DB7-9B64-502D7735D2CCQ33613070-1FCBE4B5-3729-452A-9431-8EFE5E238BFAQ33933049-6FF84FE6-9B3C-4CEC-9423-E17023EF2FD6Q33945057-B42F6847-0682-437C-9E85-A989E9B1CBA7Q34612127-D05F2829-F770-45D1-8A02-923A99FD1E65Q34751946-CD736656-749D-4816-97D9-E9A569B3C4CFQ35016935-AB490FCD-1CA0-4326-BFFA-486A731DC23AQ35076360-A62AE9A0-B0BD-4707-A7F8-5FC2A1334A66Q35532147-F761DED1-0928-4D30-AF9F-088B0B4CD263Q35804925-A3A8C569-0568-4B07-846C-D61CB9BE013BQ35977496-62304AC0-6A31-4246-8C89-674DBB7B6E0AQ36044627-4DA46EE0-C50B-43A1-B1F0-4E517B6E9EF6Q36046527-5B577A79-D0A8-44A3-929C-0F1524268E83Q36285627-A962EC11-BD9F-4F8A-B3B1-F2389FF86ADDQ36480350-BB749862-D39E-4DB2-B3A5-5CD8F923D9A8Q36522523-F0A63F00-9473-48FB-96F7-35D27C678184Q36772110-AB0B7DD3-4F28-4A76-A5DA-5A2BD84952D3Q37176840-E06CA3FA-ECBD-4707-B2A1-3B1FFF8D6E7CQ37283563-79B055F4-24AB-4E78-9253-7A92D2DC89A3Q37305943-D14CB904-5CD2-4831-A575-647F1FFA33D6Q37523962-00C85AE4-D644-4EC6-84B8-86EE9CE34D27Q37624311-B6122B4E-73DC-4B6C-8E61-C878A9433A22Q37676223-D1DC5A2D-4A8F-4B6E-A999-995DA8176A43Q37696178-A4198EE8-2C1F-41C3-8C6D-1E80C3C3D36FQ37911278-495250DF-E40A-49C8-B671-B3F47A032392Q37944437-23F710F9-DF98-454C-9874-ECCC36447B9BQ38226663-7886649C-B86E-471F-9963-7CD562CB4E9EQ38668376-39EE448F-2F00-41A1-82D8-B598C624AA78Q38840192-C9FA1991-00DA-4192-8ED5-8C705635C1A7Q38928725-84B34C4D-0EAE-4E54-A871-388E190337EAQ39040360-16412402-6D7D-48CA-BF68-7C32BC0C0157Q39284112-C61925FE-1729-4538-9AFE-4397C625D863Q41607804-F89E514A-8201-4622-984E-3529962513BBQ44681270-EA9D5CB5-C12C-4A5A-92BC-07194CBAD50AQ47109071-CA5EB74E-8E25-48E2-AD69-3E932BB0FBABQ48858566-3ED5F332-5B7F-461F-BE43-F9F7C53E0D9FQ49300793-1F3E4777-A26F-488B-BD04-27C751D9003FQ53207774-6298A2C6-3C21-403B-91C7-A9B3B3DB225C
P2860
Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Intravesical pharmacotherapy f ...... edules, and long-term results.
@ast
Intravesical pharmacotherapy f ...... edules, and long-term results.
@en
Intravesical pharmacotherapy f ...... edules, and long-term results.
@nl
type
label
Intravesical pharmacotherapy f ...... edules, and long-term results.
@ast
Intravesical pharmacotherapy f ...... edules, and long-term results.
@en
Intravesical pharmacotherapy f ...... edules, and long-term results.
@nl
prefLabel
Intravesical pharmacotherapy f ...... edules, and long-term results.
@ast
Intravesical pharmacotherapy f ...... edules, and long-term results.
@en
Intravesical pharmacotherapy f ...... edules, and long-term results.
@nl
P1433
P1476
Intravesical pharmacotherapy f ...... edules, and long-term results.
@en
P2093
J Alfred Witjes
Kees Hendricksen
P356
10.1016/J.EURURO.2007.08.015
P407
P577
2007-08-20T00:00:00Z